Hao Feng

Hao Feng has diverse work experience in the field of research and development. Hao began their career in 2010 as a Research Fellow at Texas A&M Health Science Center, where they investigated protein modification, calcium transients, and hypertrophy in primary culture cells. Hao also studied the pathological effects of reactive oxygen species (ROS) on various signaling pathways and cell viability. In 2016, they joined Baylor Scott & White Health as a Research Fellow, focusing on bioprocess development in both upstream and downstream processes.

In 2017, Hao Feng worked as a Research Associate at the University of Iowa, and in 2018, they joined the University of Alabama at Birmingham as a Researcher IV. At these institutions, they conducted research on B lymphocyte specific membrane proteins and developed immunotherapy strategies for B cell malignancies treatment, including the use of monoclonal antibodies and bi-specific antibodies.

Currently, Hao Feng is employed at transOMIC technologies inc. as a Senior Scientist and Laboratory Director. Hao'sresponsibilities include overseeing laboratory operations and conducting research. Hao'swork experience demonstrates their expertise in various aspects of research, including protein modification, cellular signaling pathways, and immunotherapy development.

Hao Feng began their education by earning a Doctor of Medicine (MD) degree in Medicine from North China Coal Medical College, where they studied from 1991 to 1996. Hao later pursued further studies and obtained a Doctor of Philosophy (PhD) degree in Physiology from Fudan University Shanghai Medical College between 1999 and 2005. To enhance their expertise, Hao Feng engaged in postdoctoral training in Cell Biology at the National Institutes of Health from 2005 to 2010.